{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:53:44Z","timestamp":1772830424245,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.lpm.2011.02.043","type":"journal-article","created":{"date-parts":[[2011,6,24]],"date-time":"2011-06-24T18:05:00Z","timestamp":1308938700000},"page":"844-849","source":"Crossref","is-referenced-by-count":9,"special_numbering":"P1","title":["Nouveaux traitements de la goutte"],"prefix":"10.1016","volume":"40","author":[{"given":"Pascal","family":"Richette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Ottaviani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2011.02.043_bib0005","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00163854","article-title":"Two independent mutational events in the loss of urate oxidase during hominoid evolution","volume":"34","author":"Wu","year":"1992","journal-title":"J Mol Evol"},{"key":"10.1016\/j.lpm.2011.02.043_bib0010","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","article-title":"Gout","volume":"375","author":"Richette","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.02.043_bib0015","first-page":"2093","article-title":"Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study","volume":"34","author":"Richette","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2011.02.043_bib0020","first-page":"1955","article-title":"Learning how and when to employ uricase as bridge therapy in refractory gout","volume":"34","author":"Terkeltaub","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lpm.2011.02.043_bib0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(10)60665-4","article-title":"Gout therapeutics: new drugs for an old disease","volume":"377","author":"Burns","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.02.043_bib0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","article-title":"PEG-uricase in the management of treatment-resistant gout and hyperuricemia","volume":"60","author":"Sherman","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.lpm.2011.02.043_bib0035","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2011.02.043_bib0040","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2011.02.043_bib0045","first-page":"CD008335","article-title":"Pegloticase for chronic gout","volume":"3","author":"Anderson","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.lpm.2011.02.043_bib0050","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/art.23993","article-title":"Resolution of gouty tophi after twelve weeks of pegloticase treatment","volume":"58","author":"Baraf","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2011.02.043_bib0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd3349","article-title":"Pegloticase","volume":"10","author":"Schlesinger","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.lpm.2011.02.043_bib0060","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2011.02.043_bib0065","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.02.043_bib0070","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2011.02.043_bib0075","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: a 28-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2011.02.043_bib0080","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A randomized controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600mg\/day versus benzbromarone 100\u2013200mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2011.02.043_bib0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.lpm.2011.02.043_bib0090","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s10067-010-1457-8","article-title":"International position paper on febuxostat","volume":"29","author":"Jansen","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.lpm.2011.02.043_bib0095","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2011.02.043_bib0100","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11926-010-0093-2","article-title":"New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond","volume":"12","author":"Schlesinger","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.lpm.2011.02.043_bib0105","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/art.22938","article-title":"The role of interleukin-1\u00a0and the inflammasome in gout: implications for therapy","volume":"56","author":"Pope","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2011.02.043_bib0110","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/ar2952","article-title":"Mechanisms of inflammation in gout","volume":"12","author":"Busso","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2011.02.043_bib0115","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.lpm.2009.01.012","article-title":"Indications of anakinra","volume":"38","author":"Chauffier","year":"2009","journal-title":"Presse Med"},{"key":"10.1016\/j.lpm.2011.02.043_bib0120","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1\u00a0inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2011.02.043_bib0125","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1136\/ard.2007.073759","article-title":"Management of treatment-resistant inflammation of acute on chronic tophaceous gout with anakinra","volume":"66","author":"McGonagle","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2011.02.043_bib0130","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/art.24694","article-title":"Case of anakinra as a steroid-sparing agent for gout inflammation","volume":"61","author":"Gratton","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2011.02.043_bib0135","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.semarthrit.2010.03.001","article-title":"Anakinra's efficacy is variable in refractory gout: report of ten cases","volume":"40","author":"Chen","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.lpm.2011.02.043_bib0140","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","article-title":"The interleukin 1\u00a0inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomized, single-blind pilot study","volume":"68","author":"Terkeltaub","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2011.02.043_bib0145","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498211002855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498211002855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T20:22:15Z","timestamp":1543695735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498211002855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0755498211002855"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2011.02.043","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}